Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Dimerix acquires Phase 2-ready asset for acute kidney injury

Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class...

July 17, 2026

Developments

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that...

July 15, 2026

Developments

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Fractyl Health (NASDAQ: GUTS) has announced positive one-year results from its REMAIN-1 Midpoint Cohort reinforcing the potential of the Revita DMR System to be the first durable procedural therapy for post-GLP-1 weight...

July 15, 2026

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Developments

Envoy reports improvement in speech perception in trial of cochlear implant

Envoy Medical (NASDAQ: COCH) has announced positive 12-month data from the first ten participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant...

July 14, 2026

Developments

Valion advances integrated biodefense, immunology platform

Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated...

July 14, 2026

Developments

VERAXA, Ardigen launch drug discovery collaboration

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates. According to VERAXA, the...

July 13, 2026

Developments

Virax signs immune profiling product supply deal with Fosun

Virax Biolabs (NASDAQ: VRAX) has announced the signing of an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma (600196.SS; 02196.HK), for its research-use-only ImmuneSelect...

July 13, 2026

Developments

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

Thiogenesis Therapeutics (TSXV: TTI; OTCQX: TTIPF) has announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. Upon approval of a...

July 13, 2026

Developments

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid...

July 10, 2026

Developments

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal...

July 10, 2026

Developments

Rani and PegBio join forces to expand obesity pipeline

Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic...

July 10, 2026

Developments

Evogene and BCDD collaborate in drug discovery initiative

Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating...

July 9, 2026

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Developments

First patient dosed in Delcath’s global trial of HEPZATO in mBC

Delcath Systems (NASDAQ: DCTH) has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with...

July 9, 2026

Developments

MAIA reports strong data from trial of 3L therapy in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action...

July 9, 2026

Developments

FDA grants RPDD to Vanda’s investigational CMT2S therapy

Vanda Pharmaceuticals (NASDAQ: VNDA) has announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its investigational antisense oligonucleotide therapy—VCA-894A—for the treatment of Charcot-Marie...

July 8, 2026

Developments

FDA accepts Organogenesis’ ReNu BLA for knee OA

Organogenesis Holdings (NASDAQ: ORGO) has announced that the FDA has accepted for review its Biologics License Application (BLA) for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of...

July 7, 2026

Developments

Alligator highlights first patient dosed in trial of mitazalimab in breast cancer

Alligator Bioscience (STO: ATORX) has announced that the first patient has been dosed in an investigator-led trial evaluating the intratumoral administration of mitazalimab, the company’s lead CD40 agonist, in patients...

July 2, 2026

Developments

FDA grants Sonoma 510(k) clearance for Microdacyn Wound Irrigation Solution

Sonoma Pharmaceuticals (NASDAQ: SNOA) has received a new 510(k) clearance from the FDA for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging...

June 30, 2026

Subscribe